Home
Team
Russell Hirsch
David Schnell
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News

Prospect Venture Partners

Home
Team
Russell Hirsch
David Schnell
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News
David Schnell
July 27, 2020

July 27, 2020 - NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

David Schnell
July 27, 2020

Source:https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-announces-initiation-phase-2-catalina-study-ngm621

Newer PostAug 29, 2020 - NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study of Aldafermin at Digital International Liver Congress (ILC) 2020 and Enrollment Completed in Phase 2b ALPINE Study
Older PostJune 15, 2020 - Iveric Bio Announces Positive Zimura 18 Month Data Supporting Efficacy Findings with Favorable Safety Profile in Geographic Atrophy Secondary to AMD in a Phase 3 Trial

Contact Prospect
Venture Partners:

Address:
525 University Ave., Suite 1350
Palo Alto, CA 94301

Phone:
(650) 327-8800

Prospect Ventures Funds:
Prospect Venture Partners I
Prospect Venture Partners II
Prospect Venture Partners III

 Connect with Prospect Ventures:
 Prospect Ventures on LinkedIn
 Prospect Ventures on Crunchbase
 Prospect Ventures on Bloomberg
 Prospect Ventures on CB Insights
 Prospect Ventures on Palico
 Prospect Ventures on Index.co
 Prospect Bio Ventures

Back to Top

© 2018 - Prospect Venture Partners.. All Rights Reserved
No content on this site may be republished or reprinted without written permission from Prospect Venture Partners